The Promise of Nanotechnology in Personalized Medicine

Overview

Journal J Pers Med

Date 2022 May 28

PMID 35629095

Authors

Maha Ali Alghamdi

Antonino N Fallica

Nicola Virzi

Prashant Kesharwani

Valeria Pittala

Khaled Greish

Affiliations

Soon will be listed here.

Abstract

Both personalized medicine and nanomedicine are new to medical practice. Nanomedicine is an application of the advances of nanotechnology in medicine and is being integrated into diagnostic and therapeutic tools to manage an array of medical conditions. On the other hand, personalized medicine, which is also referred to as precision medicine, is a novel concept that aims to individualize/customize therapeutic management based on the personal attributes of the patient to overcome blanket treatment that is only efficient in a subset of patients, leaving others with either ineffective treatment or treatment that results in significant toxicity. Novel nanomedicines have been employed in the treatment of several diseases, which can be adapted to each patient-specific case according to their genetic profiles. In this review, we discuss both areas and the intersection between the two emerging scientific domains. The review focuses on the current situation in personalized medicine, the advantages that can be offered by nanomedicine to personalized medicine, and the application of nanoconstructs in the diagnosis of genetic variability that can identify the right drug for the right patient. Finally, we touch upon the challenges in both fields towards the translation of nano-personalized medicine.

Citing Articles

Delving Into Nanoparticle Systems for Enhanced Drug Delivery Technologies.

Abaidullah N, Muhammad K, Waheed Y AAPS PharmSciTech. 2025; 26(3):74.

PMID: 40038143 DOI: 10.1208/s12249-025-03063-1.

Nanoparticle-Encapsulated Plant Polyphenols and Flavonoids as an Enhanced Delivery System for Anti-Acne Therapy.

Puspadewi R, Milanda T, Muhaimin M, Chaerunisaa A Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006023 PMC: 11858878. DOI: 10.3390/ph18020209.

Nanotechnology-Based Therapeutics for Airway Inflammatory Diseases.

Cui L, Yang Y, Hao Y, Zhao H, Zhang Y, Wu T Clin Rev Allergy Immunol. 2025; 68(1):12.

PMID: 39928241 PMC: 11811441. DOI: 10.1007/s12016-024-09019-w.

Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases.

Parvin N, Joo S, Mandal T J Funct Biomater. 2025; 16(1).

PMID: 39852580 PMC: 11766201. DOI: 10.3390/jfb16010024.

Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery.

Tenchov R, Hughes K, Ganesan M, Iyer K, Ralhan K, Lotti Diaz L ACS Nano. 2025; 19(4):4011-4038.

PMID: 39823199 PMC: 11803921. DOI: 10.1021/acsnano.4c09566.

References

Sauraj , Kumar V, Kumar B, Deeba F, Bano S, Kulshreshtha A . Lipophilic 5-fluorouracil prodrug encapsulated xylan-stearic acid conjugates nanoparticles for colon cancer therapy. Int J Biol Macromol. 2019; 128:204-213. DOI: 10.1016/j.ijbiomac.2019.01.101. View

Tariq M, Alam M, Singh A, Iqbal Z, Panda A, Talegaonkar S . Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations. Colloids Surf B Biointerfaces. 2015; 128:448-456. DOI: 10.1016/j.colsurfb.2015.02.043. View

Zhao G, Huang J, Xue K, Si L, Li G . Enhanced intestinal absorption of etoposide by self-microemulsifying drug delivery systems: roles of P-glycoprotein and cytochrome P450 3A inhibition. Eur J Pharm Sci. 2013; 50(3-4):429-39. DOI: 10.1016/j.ejps.2013.08.016. View

Witten J, Ribbeck K . The particle in the spider's web: transport through biological hydrogels. Nanoscale. 2017; 9(24):8080-8095. PMC: 5841163. DOI: 10.1039/c6nr09736g. View

Jiang T, Minunni M, Wilson P, Zhang J, Turner A, Mascini M . Detection of TP53 mutation using a portable surface plasmon resonance DNA-based biosensor. Biosens Bioelectron. 2005; 20(10):1939-45. DOI: 10.1016/j.bios.2004.08.040. View

Dai Q, Walkey C, Chan W . Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting. Angew Chem Int Ed Engl. 2014; 53(20):5093-6. DOI: 10.1002/anie.201309464. View

Cone R . Barrier properties of mucus. Adv Drug Deliv Rev. 2009; 61(2):75-85. DOI: 10.1016/j.addr.2008.09.008. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

10.

Sykes E, Dai Q, Sarsons C, Chen J, Rocheleau J, Hwang D . Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc Natl Acad Sci U S A. 2016; 113(9):E1142-51. PMC: 4780626. DOI: 10.1073/pnas.1521265113. View

11.

Wilson R, Espinosa-Diez C, Kanner N, Chatterjee N, Ruhl R, Hipfinger C . MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nat Commun. 2016; 7:13597. PMC: 5133658. DOI: 10.1038/ncomms13597. View

12.

Li A, Bergan R . Clinical trial design: Past, present, and future in the context of big data and precision medicine. Cancer. 2020; 126(22):4838-4846. PMC: 7693060. DOI: 10.1002/cncr.33205. View

13.

Tao J, Zhao P, Zheng J, Wu C, Shi M, Li J . Electrochemical detection of type 2 diabetes mellitus-related SNP via DNA-mediated growth of silver nanoparticles on single walled carbon nanotubes. Chem Commun (Camb). 2015; 51(86):15704-7. DOI: 10.1039/c5cc05520b. View

14.

Zan Y, Dai Z, Liang L, Deng Y, Dong L . Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment. Drug Deliv. 2019; 26(1):1080-1091. PMC: 6882497. DOI: 10.1080/10717544.2019.1654040. View

15.

Idris A, Davis A, Supramaniam A, Acharya D, Kelly G, Tayyar Y . A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther. 2021; 29(7):2219-2226. PMC: 8118699. DOI: 10.1016/j.ymthe.2021.05.004. View

16.

Li X, Vinothini K, Ramesh T, Rajan M, Ramu A . Combined photodynamic-chemotherapy investigation of cancer cells using carbon quantum dot-based drug carrier system. Drug Deliv. 2020; 27(1):791-804. PMC: 7301704. DOI: 10.1080/10717544.2020.1765431. View

17.

Voltan R, Secchiero P, Ruozi B, Forni F, Agostinis C, Caruso L . Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts. Clin Cancer Res. 2013; 19(14):3871-80. DOI: 10.1158/1078-0432.CCR-13-0015. View

18.

Han H, Shin H, Ha D . Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system. Eur J Pharm Sci. 2012; 46(5):500-7. DOI: 10.1016/j.ejps.2012.04.002. View

19.

Ni W, Li Z, Liu Z, Ji Y, Wu L, Sun S . Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma. J Pharm Sci. 2018; 108(3):1284-1295. DOI: 10.1016/j.xphs.2018.10.042. View

20.

Walcher L, Kistenmacher A, Suo H, Kitte R, Dluczek S, Strauss A . Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol. 2020; 11:1280. PMC: 7426526. DOI: 10.3389/fimmu.2020.01280. View